ReviewCancers2021
Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Human biomarker navigator.iMeta · 2026Review
- Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin.Antibody therapeutics · 2026Article
- Integrated miR-omics and proteomics reveal the regulatory role of miR in protein networks associated with COVID-19 disease progression.Frontiers in immunology · 2026Article
- Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation.Cancer biology & therapy · 2025Review
- Development of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma.Bioconjugate chemistry · 2025Article
- Computational modeling and experimental validation of the interaction between tumor biomarker mesothelin and an engineered targeting protein with therapeutic activity.Protein science : a publication of the Protein Society · 2025Article
- Review
- A Diagnostic Approach to Malignant Pleural Mesothelioma.Pulmonary therapy · 2025Article
- Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities.Cancers · 2025Review
- Radical hemithorax radiotherapy induces an increase in circulating PD-1Frontiers in immunology · 2025Article
- Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score.Oncology · 2025Article
- Malignant Pleural Mesothelioma: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas.Frontiers in veterinary science · 2024Article
- Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.Journal of clinical medicine · 2023Review
- Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.Biomolecules · 2023Article
- Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?International journal of molecular sciences · 2023Review
- Challenges of Anti-Mesothelin CAR-T-Cell Therapy.Cancers · 2023Review
- Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.Cancer research communications · 2023Article
- Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody-drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.